PRECISION MEDICINE GIVING HOPE

BIOHOPE expresses a strong interest to participate in the initiatives to fight against COVID-19 launched by the Spanish Ministry and the European Commission

Biohope is a clinical stage biotech company, dedicated to the development of unique precision medicine IVD tools for chronic inflammatory/autoimmune conditions to improve clinical outcomes by allowing the personalization and optimization of current and future treatments. Our lead innovation, Immunobiogram®, is a novel, unique and patented technology platform which provides physicians with important information to optimize the use of specific drugs and dosages of immunosuppressive therapies for individual patients. Immunobiogram® combines a biotechnological kit and a software for data interpretation to elaborate individualized reports. There is no other product providing similar information.

As a consequence of the coronavirus COVID-2019 pandemia, Biohope´s scientific team has made an assessment on the possibilities to apply the Immunobiogram® technology to help fighting Covid-19 because knowing each patient´s immune system situation could be very valuable to treat COVID-19 patients

Biohope, arrived to the conclusion that the Immunobiogram® technology could be a very helpful tool against the COVID-19 infection. The Immunobiogram ® is a bioassay to test the immune system, and it is known the immune system situation of a patient plays a key role in the prognosis and consequences of the infection.

Biohope has developed a research project called "Immunological evaluation in Covid-19 infection to develop novel prognosis IVD tools and study of immunomodulator drugs ", and is seeking funding from the Spanish Ministry of Health and the European Commission.

This project could deliver a proof-of-concept of a novel functional immunoassay that may prove useful in Covid-19 infection in two ways:

1) As a prognosis tool, informing about the functionality of adaptive T-cell driven response to the disease, that is linked to morbimortality. The Immunobiogram ® may complement absolute leucocyte count adding functional information about the immune system.

2) As an informative tool about the in vitro potency of a panel of immunomodulators, currently being used for severe cases and under a trial/error experience.

The requested funds would be immediately used to start a clinical study with several hospitals in Madrid. This study would allow to better select the high risk patients so they can be treated faster and more intensely right after diagnosing each positive COVID-19 case. Also, the individual treatment response can be anticipated, helping to improve the prognosis and diminish the development of pneumonia.